Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Not Recruiting

Trial ID: NCT04167761

Age - 18 Years-80 Years Gender - All Accepting Healthy Volunteers - No

Purpose

The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.

Official Title

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Stanford Investigator(s)

Tracey McLaughlin
Tracey McLaughlin

Professor of Medicine (Endocrinology)

Eligibility


Inclusion Criteria:

   - patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass
   surgery

   - history of Diabetes Mellitus Type 2 currently taking metformin or diet-controlled

Exclusion Criteria:

   - allergy or intolerance to interventional medication

   - currently taking any anti-diabetic medication other than metformin

View More
View Less

Intervention(s):

drug: Ertugliflozin

drug: Glipizide

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Tracey McLaughlin, MD
650-736-2056

©2022 Stanford Medicine